Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EirGenix Makes Progress With Trastuzumab Biosimilar

Company Plans To Submit Filings To Both FDA and EMA

Executive Summary

Taiwan’s EirGenix has made progress with its trastuzumab biosimilar for breast cancer, EG12014, announcing positive Phase III clinical results for the Herceptin equivalent. 

You may also be interested in...



Sandoz EMA Trastuzumab Application Follows US Filing

Sandoz and EirGenix have followed their US filing for a biosimilar rival to Herceptin with a European filing for the EG12014 trastuzumab candidate.

Sandoz Files US Trastuzumab With EirGenix

Sandoz has filed the proposed trastuzumab biosimilar developed by partner EirGenix with the US FDA. If approved, the product will have to compete in an already busy market for Herceptin biosimilars.

Fifth US Biosimilar To Herceptin Launched By Merck

Merck & Co has launched Ontruzant, the trastuzumab biosimilar developed and manufactured by Samsung Bioepis, in the US following a staggered approval process and earlier intellectual-property hurdles. The list price discount offered by the firm puts it in the middle of the pack among the four other biosimilar players currently on the market.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel